ACE Inhibitors Global Market Report 2026

ACE inhibitors, or angiotensin-converting enzyme inhibitors, are a class of medications used for the treatment and management of hypertension. They work by inhibiting the enzyme responsible for producing angiotensin II, a substance that causes blood vessels to narrow and increases blood pressure. Their primary role is to relax arteries and veins, thereby lowering blood pressure.

The primary categories of ACE inhibitors include sulfhydryl-containing agents, dicarboxylate-containing agents, and phosphonate-containing agents. Sulfhydryl-containing agents are compounds characterized by the presence of a sulfhydryl group (-SH) in their chemical structure. Drugs in this category include ramipril, enalapril, benazepril, fosinopril, captopril, moexipril, and others, which are available in multiple dosage forms such as oral tablets and oral solutions. These medications are used across a range of applications, including heart failure, chronic kidney disease, hypertension, diabetes, heart attack, and others, and are distributed through various end users such as hospitals, online drug stores, and others.

Tariffs have affected the ACE inhibitors market by increasing the cost of imported active pharmaceutical ingredients and raw materials, leading to higher production costs for manufacturers. This impact is most pronounced in regions like North America and Europe, where reliance on imports is significant, and in segments producing specialized or patented ACE inhibitors. Some manufacturers benefit from tariffs by shifting to local sourcing, boosting domestic production, and promoting local pharmaceutical industries, which can enhance supply chain resilience and market stability.

The ace inhibitors market research report is one of a series of new reports from The Business Research Company that provides ace inhibitors market statistics, including ace inhibitors industry global market size, regional shares, competitors with a ace inhibitors market share, detailed ace inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the ace inhibitors industry. This ace inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ace inhibitors market size has grown strongly in recent years. It will grow from $7.41 billion in 2025 to $7.84 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increasing prevalence of hypertension, rising awareness about cardiovascular diseases, introduction of first-generation ace inhibitors, growing geriatric population, advancements in drug formulation.

The ace inhibitors market size is expected to see strong growth in the next few years. It will grow to $10.11 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to demand for personalized medicine, integration of digital health solutions, expansion of emerging markets, development of novel ace inhibitor combinations, growth in home healthcare services. Major trends in the forecast period include personalized hypertension management, telemedicine & remote patient monitoring, combination therapy development, rise in generic ace inhibitors, expansion of home healthcare solutions.

The rising incidence of cardiac disorders is expected to drive the growth of the ACE inhibitors market in the coming years. Cardiac disorders are a group of medical conditions that affect the heart and blood vessels and include a broad spectrum of diseases such as coronary artery disease, heart failure, and arrhythmias. ACE inhibitors play a vital role in managing cardiac disorders by blocking the angiotensin-converting enzyme, which helps reduce vasoconstriction, sodium retention, and aldosterone secretion, ultimately improving overall cardiac function. For example, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted mortality rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, representing a 4.0% increase from 224.4 per 100,000 in 2023. As a result, the increasing prevalence of cardiac disorders is contributing to the expansion of the ACE inhibitors market.

Major companies operating in the ACE inhibitor market are placing greater emphasis on the introduction of generic drugs to strengthen their competitive position. A generic drug is defined as a medication that contains the same active ingredients, dosage, strength, safety, route of administration, and therapeutic effectiveness as a branded drug, but is typically offered at a lower cost after patent expiration. For instance, in August 2023, Pharmascience Inc., a Canada-based pharmaceutical company, introduced pms-PERINDOPRIL-INDAPAMIDE, a generic product intended for the initial treatment of mild to moderate essential hypertension in adults. This combination therapy contains two active ingredients: perindopril erbumine, an angiotensin-converting enzyme inhibitor that helps relax blood vessels, and indapamide, a chlorosulphamoyl diuretic that promotes the elimination of excess fluid and sodium from the body. Together, these components work synergistically to lower blood pressure across a broad patient population. pms-PERINDOPRIL-INDAPAMIDE is available in multiple dosage strengths, including 2 mg, 4 mg, and 8 mg of perindopril erbumine combined with 0.625 mg, 1.25 mg, and 2.5 mg of indapamide, respectively.

In January 2023, AstraZeneca, a UK-based pharmaceutical company, acquired CinCor Pharma for $1.3 billion. This acquisition is expected to support AstraZeneca's expansion of its aldosterone synthase inhibitor (ASI) portfolio for blood pressure reduction in patients with treatment-resistant hypertension. CinCor Pharma is a US-based clinical-stage biopharmaceutical company focused on developing innovative therapies for resistant and uncontrolled hypertension, as well as chronic kidney disease.

Major companies operating in the ace inhibitors market are Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy's Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

North America was the largest region in the ACE inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ace inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The global ACE inhibitors market consists of sales of various drugs including zofenopril, perindopril, enalapril, trandolapril. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

ACE Inhibitors Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses ace inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ace inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ace inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Sulfhydryl-containing Agents; Dicarboxylate-containing Agents; Phosphonate-containing Agents
• 2) By Drug: Ramipril; Enalapril; Benazepril; Fosinopril; Captopril; Moexipril; Other Drugs
• 3) By Dosage Form: Oral Tablets; Oral Solutions
• 4) By Application: Heart Failure; Chronic Kidney Disease; Hypertension; Diabetes; Heart Attack; Other Applications
• 5) By End-Users: Hospitals; Online Drug Stores; Other End-Users
• Subsegments:
• 1) By Sulfhydryl-Containing Agents: Captopril; Zofenopril
• 2) By Dicarboxylate-Containing Agents: Enalapril; Lisinopril; Ramipril; Quinapril; Benazepril; Perindopril
• 3) By Phosphonate-Containing Agents: Fosinopril; Fosinopril Sodium; Fosinopril Calcium
• Companies Mentioned: Pfizer Inc.; Novartis AG; Johnson & Johnson Private Limited; Merck KGaA; Sanofi S.A.; Bayer AG; Teva Pharmaceutical Industries Ltd.; Bristol-Myers Squibb Co.; Takeda Pharmaceuticals Company; Daiichi Sankyo Company Ltd.; Endo International plc; Sun Pharmaceutical Industries Ltd.; Boehringer Ingelheim; Bausch Health Companies Inc.; Dr. Reddy's Laboratories; Abbott Laboratories; Eli Lilly and Company; Cipla Limited; GlaxoSmithKline plc; Cadila Healthcare Limited; AbbVie Inc.; Sandoz Group AG; Accord Healthcare Ltd.; AstraZeneca plc; Lupin Limited; Macleods Pharmaceuticals Limited; Zydus lifescience Ltd.; Apotex Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.